Drug
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate clinical trials
Also written MK-1439A.
- studies test it
- 11
- open now
- 1
- in phase 3
- 3
- first study started
- 2016
Keep track of what changes. Save the Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 4
- Phase 3
- 3
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 9
Professor Francois Venter (2) · Merck Sharp & Dohme LLC (2) · Hospital Clinic of Barcelona (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University Hospital, Caen (1) · Chelsea and Westminster NHS Foundation Trust (1) · University Health Network, Toronto (1) · Thomas Benfield (1)
Often tested with
Tested in the same studies.
Doravirine (2) · Islatravir (1) · Lamivudine (1) · Dolutegravir (1) · Dolutegravir Sodium/Lamivudine (1) · Bictegravir (1) · Emtricitabine (1) · Tenofovir alafenamide (1)
Studies
Open first, then newest update. How each study uses Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is read from its arms, and is right about nine times in ten.
Testing it · 11
- DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)RecruitingPhase 2University Hospital, CaenNCT06034938Written as Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
- The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive PatientsTerminatedPhase 4Chelsea and Westminster NHS Foundation TrustNCT05289986Written as DELSTRIGO 100Mg-300Mg-300Mg Tablet
- Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label StudyCompletedPhase 4Hospital Clinic of BarcelonaNCT04233372Written as Delstrigo
- Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?TerminatedPhase 4University Health Network, TorontoNCT04665375Written as DOR/3TC/TDF
- A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral TherapyActive, not recruitingPhase 3Professor Francois VenterNCT05924438Written as Delstrigo
- DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIVCompletedPhase 3Professor Francois VenterNCT04433780Written as Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
- Doravirine and Weight Gain in Antiretroviral NaiveWithdrawnPhase 3Prism Health North TexasNCT05457530Written as DOR/3TC/TDF
- Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)CompletedPhase 2Merck Sharp & Dohme LLCNCT03272347Written as Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
- Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and AdolescentsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03332095Written as Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)
- Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)CompletedPhase 2Merck Sharp & Dohme LLCNCT02629822Written as Doravirine/lamivudine/tenofovir disoproxil fumarate
- Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir DisproxilStatus unknownPhase 4Thomas BenfieldNCT04903847Written as Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]